Effect of metallo-β-lactamase production and multidrug resistance on clinical outcomes in patients with Pseudomonas aeruginosabloodstream infection: a retrospective cohort study

Table 5 Multivariate analysis: Hazard ratios for deaths and discharge (dead or alive)

Parameter	Hazard ratio for deaths (95% CI)	P-value	Hazard ratio for discharge–fully adjusted (95% CI)	P-value	Hazard ratio for discharge–fully adjusted (95% CI) only survivors (n = 70)	P-value
MBL-PA	0.98 (0.45-2.1)^a	0.97	1.28 (0.63-2.58)^c	0.49	1.53 (0.53-4.45)^e	0.44
3/4MDR-PA	1.37 (0.68-2.72)^b	0.37	1.24 (0.69-2.21)^d	0.46	0.75 (0.31-1.83)^f	0.53

^aSignificant in the same model: SAPS II (HR 1.046, P < 0.001), cardiovascular disease (HR 0.44, P = 0.015) and ADT (HR 0.25, P = 0.002).
^bSignificant in the same model: SAPS II (HR 1.046, P < 0.001), cardiovascular disease (HR 0.46, P = 0.025) and ADT (HR 0.26, P = 0.003).
^cSignificant in the same model: Concomitant infection (HR 0.3, P < 0.001), ADT (HR 0.39, P = 0.004).
^dSignificant in the same model: Concomitant infection (HR 0.27, P < 0.001), ADT (HR 0.4, P = 0.007).
^eSignificant in the same model: Concomitant infection (HR 0.32, P = 0.002), vascular catheter-related BSI (HR 0.41, P = 0.04), nosocomial infection (HR 0.44, P = 0.04).
^fSignificant in the same model: Concomitant infection (HR 0.32, P = 0.002), neutropenia (HR 0.39, P = 0.006), nosocomial infection (HR 0.37, P = 0.004), ADT (HR 0.25, P = 0.008).
95% CI, 95% Confidence interval; MBL-PA, metallo-β-lactamase producing Pseudomonas aeruginosa; 3/4MDR-PA, 3/4MDR-Pseudomonas aeruginosa; SAPS II, Simplified Acute Physiology Score; ADT, appropriate definitive treatment.

ISSN: 1471-2334